BioSpace News Archive

InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10, 2020, to discuss financial results for the fourth quarter and year ended December 31, 2019, and provide a corporate update.

Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced the addition of experienced biotech executive Ms. Pamela Yanchik Connealy to its Board of Directors as Audit Committee chair.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a medical technology company focused on Women’s Health, initially in the breast aesthetics and reconstruction market, today announced the Company will release its financial results for the fourth quarter ended December 31, 2019, before the market opens on Monday, March 16, 2020.

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller University under which Celldex performed manufacturing and development services for Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including two clinical-stage candidates 3BNC117 and 10-1074.

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based institutional investor.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), today announced that the results from its pivotal cellulite trial have been accepted for oral presentation at the American Academy of Dermatology (AAD) 2020 Annual Meeting, being held March 20-24 in Denver, CO.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announces as of February 2020, a patient from the Phase 1 clinical trial for the treatment of glioblastoma multiforme (“GBM”), conducted by Reata Pharmaceuticals, Inc

MAX BioPharma, Inc. (www.maxbiopharma.com) recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed journal, Cells. (https://www.mdpi.com/2073-4409/8/10/1297/pdf).

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will release its fourth quarter and full year 2019 financial results before the market opens on Thursday, March 12, 2020

BioIVT’s acquisition of Clinical Trial Laboratory Services (CTLS) and its London donor center is enabling this rapid turnaround time for high quality blood-derived immune cells for cell and gene therapy research